Gaudium IVF revenue climbs 48% as it targets 10 new hubs
The fertility chain is deploying IPO proceeds to scale its domestic footprint and launch international centers in Paris, Nigeria, and Sydney.
— 1 earlier story on Gaudium IVF and Women Health Ltd. →What's new
- Revenue grew 47.6% to ₹104.35 cr for the year ended March 2026.
- Management plans to add 10 new hubs in FY27 using IPO funds.
- AI-driven embryology tools improved clinical success rates by 8%.
Why this matters
Gaudium is pivoting from a local player to a global chain. The 8% gain in success rates provides a tangible clinical edge that justifies its push into high-margin medical tourism markets like Paris and Sydney.
What we're watching
- Margin recovery after the current phase of pre-opening costs.
- Execution of the 10-hub expansion target within the next fiscal year.
- Revenue contribution from the new international centers.
The full read
Gaudium IVF is moving into a rapid growth phase. The company reported ₹104.35 crore in revenue for FY26, a 47.6% jump that signals strong demand for its fertility services. Management is now pivoting to an asset-light, hub-and-spoke model, with plans to open 10 new domestic hubs this year using IPO proceeds. The firm is also betting on technology to drive its premium positioning, reporting an 8% improvement in clinical success rates since implementing AI-driven embryology tools. International expansion is the next frontier, with centers planned for Paris, Nigeria, and Sydney to tap into high-margin medical tourism. While pre-opening costs compressed margins this year, the company’s debt-light balance sheet provides a buffer for its ₹25 crore capital expenditure budget for FY27. The goal is to reach 19 total hubs within three years. It is a clear attempt to scale quickly while using clinical data to stand out in a crowded market.
Questions answered
- How is Gaudium funding its expansion?
- The company is utilizing funds from its recent IPO to add 10 new hubs domestically. It has also earmarked ₹25 crore for capital expenditure in FY27.
- What is the impact of the new AI tools?
- The integration of AI-driven embryology tools has improved clinical success rates by 8% since April. This data is being used to differentiate the company's service offering.
- Why is the company expanding into international markets?
- Gaudium is targeting Paris, Nigeria, and Sydney to capture higher-margin medical tourism volume. This is part of a broader strategy to scale its hub-and-spoke model.
- How did the company perform financially this year?
- Revenue reached ₹104.35 crore, representing a 47.6% increase over the prior year. While margins faced pressure from scaling and pre-opening costs, the company maintains a debt-light balance sheet.
Story so far
All notes on GAUDIUMIVF →- 29 May 2026 · 1:11 PM IST Gaudium IVF revenue climbs 48% as it targets 10 new hubs
- 1d ago Gaudium IVF revenue climbs 48% in consolidated FY26 results